DK2501704T3 - Spiropiperidinforbindelser som oral-1-receptorantagonister - Google Patents

Spiropiperidinforbindelser som oral-1-receptorantagonister

Info

Publication number
DK2501704T3
DK2501704T3 DK10782486.4T DK10782486T DK2501704T3 DK 2501704 T3 DK2501704 T3 DK 2501704T3 DK 10782486 T DK10782486 T DK 10782486T DK 2501704 T3 DK2501704 T3 DK 2501704T3
Authority
DK
Denmark
Prior art keywords
oral
receptor antagonists
spiropiperidine compounds
spiropiperidine
compounds
Prior art date
Application number
DK10782486.4T
Other languages
Danish (da)
English (en)
Inventor
Collado Ana Belen Benito
Buezo Nuria Diaz
Alma Maria Jimenez-Aguado
Blanco Celia Lafuente
Maria Angeles Martinez-Grau
Concepcion Pedregal-Tercero
Escribano Miguel Angel Toledo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK2501704T3 publication Critical patent/DK2501704T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK10782486.4T 2009-11-16 2010-11-12 Spiropiperidinforbindelser som oral-1-receptorantagonister DK2501704T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382245 2009-11-16
US29862810P 2010-01-27 2010-01-27
PCT/US2010/056449 WO2011060217A1 (en) 2009-11-16 2010-11-12 Spiropiperidine compounds as orl-1 receptor antagonists

Publications (1)

Publication Number Publication Date
DK2501704T3 true DK2501704T3 (da) 2013-10-14

Family

ID=41800752

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10782486.4T DK2501704T3 (da) 2009-11-16 2010-11-12 Spiropiperidinforbindelser som oral-1-receptorantagonister

Country Status (18)

Country Link
US (1) US20120214784A1 (https=)
EP (1) EP2501704B1 (https=)
JP (1) JP5723381B2 (https=)
KR (1) KR101368130B1 (https=)
CN (1) CN102666550B (https=)
AU (1) AU2010319400B2 (https=)
BR (1) BR112012011710A2 (https=)
CA (1) CA2781041C (https=)
DK (1) DK2501704T3 (https=)
EA (1) EA020391B1 (https=)
ES (1) ES2436241T3 (https=)
HR (1) HRP20130969T1 (https=)
MX (1) MX2012005690A (https=)
PL (1) PL2501704T3 (https=)
PT (1) PT2501704E (https=)
RS (1) RS53017B (https=)
SI (1) SI2501704T1 (https=)
WO (1) WO2011060217A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106883246B (zh) * 2009-12-04 2020-05-29 桑诺维恩药品公司 多环化合物及其使用方法
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之orl-1受體拮抗劑
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
JO3638B1 (ar) * 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
CA3032141A1 (en) 2016-07-29 2018-02-01 Vadim ALEXANDROV Compounds and compositions and uses thereof
UA125519C2 (uk) 2016-07-29 2022-04-13 Суновіон Фармасьютікалз Інк. Сполуки і композиції і їх застосування
KR20190037305A (ko) 2016-08-10 2019-04-05 바이엘 크롭사이언스 악티엔게젤샤프트 해충 방제제로서의 치환된 2-헤테로시클릴 이미다졸릴-카르복스아미드
IL268694B2 (en) 2017-02-16 2023-10-01 Sunovion Pharmaceuticals Inc Treatment of schizophrenia
DK3589637T3 (da) * 2017-03-02 2021-06-14 Lilly Co Eli Forbindelser, der er anvendelige til inhibering af ROR-GAMMA-T
PL3589638T3 (pl) 2017-03-02 2021-09-27 Eli Lilly And Company Związki użyteczne do hamowania ror-gamma-t
BR112020001433A2 (pt) 2017-08-02 2020-07-28 Sunovion Pharmaceuticals Inc. compostos de isocromano e usos dos mesmos
EA202091945A1 (ru) 2018-02-16 2021-01-18 Суновион Фармасьютикалз Инк. Соли, кристаллические формы и способы их получения
TWI848031B (zh) 2018-12-17 2024-07-11 美商維泰克斯製藥公司 Apol1抑制劑及其使用方法
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
EP3766879A1 (en) 2019-07-19 2021-01-20 Basf Se Pesticidal pyrazole derivatives
CN115734785A (zh) 2020-04-14 2023-03-03 桑诺维恩药品公司 (S)-(4,5-二氢-7H-噻吩并[2,3-c]吡喃-7-基)-N-甲基甲胺用于治疗神经和精神方面的病症
WO2021252863A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and using the same
IL300298B2 (en) 2020-08-26 2025-06-01 Vertex Pharma Inhibitors of apol1 and methods of using same
CN119343353A (zh) * 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003235912A1 (en) 2002-05-10 2003-11-11 Taisho Pharmaceutical Co., Ltd. Spiro-ring compound
WO2005016913A1 (en) 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
CA2563164A1 (en) * 2004-03-29 2005-10-06 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
US7655670B2 (en) * 2005-06-02 2010-02-02 Janssen Pharmaceutica N.V. 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators

Also Published As

Publication number Publication date
EA020391B1 (ru) 2014-10-30
EA201290355A1 (ru) 2012-10-30
AU2010319400A1 (en) 2012-06-07
CA2781041C (en) 2015-01-06
KR101368130B1 (ko) 2014-02-27
CA2781041A1 (en) 2011-05-19
CN102666550A (zh) 2012-09-12
PL2501704T3 (pl) 2014-02-28
ES2436241T3 (es) 2013-12-27
MX2012005690A (es) 2012-06-13
PT2501704E (pt) 2013-12-05
WO2011060217A1 (en) 2011-05-19
EP2501704A1 (en) 2012-09-26
US20120214784A1 (en) 2012-08-23
SI2501704T1 (sl) 2013-11-29
RS53017B (sr) 2014-04-30
AU2010319400B2 (en) 2013-12-19
JP5723381B2 (ja) 2015-05-27
HRP20130969T1 (hr) 2013-11-22
EP2501704B1 (en) 2013-09-18
CN102666550B (zh) 2015-07-15
KR20120082927A (ko) 2012-07-24
JP2013510870A (ja) 2013-03-28
BR112012011710A2 (pt) 2016-03-01

Similar Documents

Publication Publication Date Title
DK2501704T3 (da) Spiropiperidinforbindelser som oral-1-receptorantagonister
HUS2200033I1 (hu) CGRP receptor antagonisták
DK2501703T3 (da) Spiropiperidinforbindelser som orl-1-receptorantagonister
CY2020010I1 (el) Ενωσεις oi οποιες τροποποιουν τον υποδοχεα ανδρογονου
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
DK2821407T3 (da) Piperidinoncarboxamidazaindan-cgrp receptorantagonister
DK2401269T3 (da) Indolderivater som crth2-receptorantagonister
EP2927224B8 (en) Receptor antagonists
DK2376490T3 (da) Imidazopyridinforbindelser
BRPI0923512A2 (pt) antagonistas de receptores de ácido lisofosfatídico
DK3345903T3 (da) Tetracykliske forbindelser
DK2443104T3 (da) Disubstituerede phthalazin-hedgehog-sti-antagonister
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
DK2401256T3 (da) Forbindelser som bradykinin-B1-antagonister.
HUE063115T2 (hu) Kiméra I-es típusú IL-1 receptor antagonisták
DK2539323T3 (da) Fobindelser som Bradykinin-B1-antagonister
DK2342182T3 (da) Isoquinolinonderivater som nk3-antagonister
BR112012003976A2 (pt) antagonistas de receptor glyt1 carbocíclico
DK2606042T3 (da) Disubstituerede tetrahydrofuranyl-forbindelser som antagonister af bradykinin-b1-receptor
BRPI0908008A2 (pt) Farmacóforo dual - pde4-antagonistas muscarínicos
EP2566494A4 (en) CXCR4 RECEPTOR COMPOUNDS
BR112012005119A2 (pt) novos antagonistas de hepcidina etanodiaminas
BRPI0907519A2 (pt) Antagonistas farmacoforos-pde4-muscarínicos duais
DK2456765T3 (da) Imidazolderivater som mglur5-antagonister
EP2408304A4 (en) CGRP RECEPTOR ANTAGONISTS